The Court of Appeal has ruled that employers’ vicarious liability to third parties does not transfer to new employers under Transfer of Undertakings (Protection of Employment) legislation. The landmark judgment, handed down
More
Artificial intelligence is rapidly reshaping the legal industry, and the transformation is no longer limited to the largest and most resource-rich law firms. AI-native law firms, built from the ground up around
More
Lisa Solbakken, co-founder and managing partner of Arkin Solbakken, has built a formidable reputation as a trusted adviser to elite legal professionals navigating high-stakes workplace exits. Known on Wall Street as a
More
London stocks closed sharply higher on Thursday, driven by falling bond yields and a declining oil price as markets absorbed the Bank of England’s latest rate decision. The FTSE 100 index ended
More
Bloom Energy (BE) has emerged as a company of significant interest as artificial intelligence data centre buildouts accelerate across the United States and beyond. The energy technology firm has been securing contracts
More
Paymentus Holdings (PAY) has seen its earnings outlook revised upward, prompting fresh debate about what the development means for existing and prospective shareholders. An improved earnings forecast is generally considered a positive
More
Bytes Technology Group (BYIT), a prominent FTSE 250 software and IT solutions provider, has crossed the £1 billion revenue threshold as its ongoing recovery continues to build momentum. The milestone marks a
More
The Council of the EU’s decision on an additional 8.3 billion euros is something that businessman and investor Seyar Kurshutov suggests assessing against the true scale of the reconstruction ahead. According to
More
The Saudi Pro League is giving players a new way to profit from the competition, with a revenue-sharing initiative tied to social media promotion of live match streams. The scheme, called “Share
More
Genentech, a member of the Roche Group, has announced positive results from the Phase III CELESTIMO study evaluating Lunsumio in follicular lymphoma patients. The trial assessed Lunsumio, also known as mosunetuzumab, in
More